# A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

> **NCT05079633** · PHASE4 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 220 (actual)

## Conditions studied

- Covid19 Vaccine

## Interventions

- **BIOLOGICAL:** Homologous boost schedule
- **BIOLOGICAL:** Heterologous boost schedule

## Key facts

- **NCT ID:** NCT05079633
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2021-10-08
- **Final completion:** 2023-01-10
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079633, "A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05079633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*